Clinical trials: Space Maintenance
Alveolar Bone Loss
Localized Alveolar Ridge Augmentation With Space Maintenance Devices
The purpose of this research study is to determine whether this study treatment can improve the bone structure of the upper front part of the jaw in patients who are scheduled for surgery to have a dental implant(s) placed into…
- Trial name
- Ridge Mesh (NCT00991432)
- Testing
- INFUSE® Bone Graft
- Where
- 8 sites in United States
- Volunteers
- 10 people
- Sponsor
- Medtronic Spinal and Biologics
Cataract
To Compare the Ability of DiscoVisc® OVD to Protect the Corneal Endothelium and Maintain Anterior Chamber Space With Healon® and Amvisc® PLUS During Cataract Surgery.
The objective of the study is to assess how DisCoVisc Ophthalmic Viscosurgical Device (OVD) compares with Healon and Amvisc Plus in the protection of corneal endothelial cells, and the ability to maintain anterior chamber space…
- Trial name
- NCT00763360
- Testing
- DisCoVisc®, Healon, Amvisc Plus
- Where
- United States
- Volunteers
- 184 people
- Sponsor
- Alcon Research
Prostate Cancer Patients Treated by Radiotherapy
Post-marketing Surveillance Regarding Efficacy and Safety of SpaceOAR™
A treatment with SpaceOAR™ hydrogel does reduce late toxicity Grad 2 and Grad 3 of radiation therapy in prostate cancer patients
- Trial name
- NCT01999660
- Testing
- SpaceOAR™ implantation
- Where
- Germany
- Volunteers
- 119 people
- Sponsor
- CS Diagnostics GmbH
Chronic Kidney Disease, Anemia
A Study of Four Dosing Regimens of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease. Protocol Addendum: Extension Study of Maintenance Therapy of PROCRIT (Epoetin Alfa) in Patients With Chronic Kidney Disease.
The primary objective of this study is to compare the change in hemoglobin (Hb) from study start to the end of the study between the every 2 week and the every 4 week dosing regimens in patients with anemia of chronic kidney…
- Trial name
- NCT00212875
- Testing
- epoetin alfa
- Volunteers
- 267 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.